Randomized	B:C0034656
Crossover	O
Trial	I:C0150097
of	O
Amoxapine	O
Versus	O
Vitamin	O
B12	I:C0042845
for	O
Retrograde	O
Ejaculation	I:C0403673
.	O

Randomized	O
Crossover	B:C0150097
Trial	I:C0150097
of	O
Amoxapine	O
Versus	O
Vitamin	O
B12	I:C0042845
for	O
Retrograde	O
Ejaculation	I:C0403673
.	O

Randomized	O
Crossover	O
Trial	I:C0150097
of	O
Amoxapine	B:C0002644
Versus	O
Vitamin	O
B12	I:C0042845
for	O
Retrograde	O
Ejaculation	I:C0403673
.	O

Randomized	O
Crossover	O
Trial	I:C0150097
of	O
Amoxapine	O
Versus	O
Vitamin	B:C0042845
B12	I:C0042845
for	O
Retrograde	O
Ejaculation	I:C0403673
.	O

Randomized	O
Crossover	O
Trial	I:C0150097
of	O
Amoxapine	O
Versus	O
Vitamin	O
B12	I:C0042845
for	O
Retrograde	B:C0403673
Ejaculation	I:C0403673
.	O

To	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
amoxapine	B:C0002644
and	O
vitamin	O
B12	I:C0042845
for	O
treating	O
retrograde	O
ejaculation	I:C0403673
(	O
retrograde	O
ejaculation	I:C0403673
)	O
.	O

To	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
amoxapine	O
and	O
vitamin	B:C0042845
B12	I:C0042845
for	O
treating	O
retrograde	O
ejaculation	I:C0403673
(	O
retrograde	O
ejaculation	I:C0403673
)	O
.	O

To	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
amoxapine	O
and	O
vitamin	O
B12	I:C0042845
for	O
treating	B:C0087111
retrograde	O
ejaculation	I:C0403673
(	O
retrograde	O
ejaculation	I:C0403673
)	O
.	O

To	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
amoxapine	O
and	O
vitamin	O
B12	I:C0042845
for	O
treating	O
retrograde	B:C0403673
ejaculation	I:C0403673
(	O
retrograde	O
ejaculation	I:C0403673
)	O
.	O

To	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
amoxapine	O
and	O
vitamin	O
B12	I:C0042845
for	O
treating	O
retrograde	O
ejaculation	I:C0403673
(	O
retrograde	B:C0403673
ejaculation	I:C0403673
)	O
.	O

Between	O
May	O
2009	O
and	O
November	O
2012	O
,	O
this	O
open	B:C1709323
-	I:C1709323
label	I:C1709323
,	O
randomized	O
,	O
crossover	O
study	I:C0150097
enrolled	O
26	O
men	O
suffering	O
with	O
retrograde	O
ejaculation	I:C0403673
at	O
Department	O
of	O
Reproductive	O
Medicine	O
,	O
Omori	O
Hospital	O
.	O

Between	O
May	O
2009	O
and	O
November	O
2012	O
,	O
this	O
open	O
-	I:C1709323
label	I:C1709323
,	O
randomized	B:C0034656
,	O
crossover	O
study	I:C0150097
enrolled	O
26	O
men	O
suffering	O
with	O
retrograde	O
ejaculation	I:C0403673
at	O
Department	O
of	O
Reproductive	O
Medicine	O
,	O
Omori	O
Hospital	O
.	O

Between	O
May	O
2009	O
and	O
November	O
2012	O
,	O
this	O
open	O
-	I:C1709323
label	I:C1709323
,	O
randomized	O
,	O
crossover	B:C0150097
study	I:C0150097
enrolled	O
26	O
men	O
suffering	O
with	O
retrograde	O
ejaculation	I:C0403673
at	O
Department	O
of	O
Reproductive	O
Medicine	O
,	O
Omori	O
Hospital	O
.	O

Between	O
May	O
2009	O
and	O
November	O
2012	O
,	O
this	O
open	O
-	I:C1709323
label	I:C1709323
,	O
randomized	O
,	O
crossover	O
study	I:C0150097
enrolled	O
26	O
men	B:C0025266
suffering	O
with	O
retrograde	O
ejaculation	I:C0403673
at	O
Department	O
of	O
Reproductive	O
Medicine	O
,	O
Omori	O
Hospital	O
.	O

Between	O
May	O
2009	O
and	O
November	O
2012	O
,	O
this	O
open	O
-	I:C1709323
label	I:C1709323
,	O
randomized	O
,	O
crossover	O
study	I:C0150097
enrolled	O
26	O
men	O
suffering	O
with	O
retrograde	B:C0403673
ejaculation	I:C0403673
at	O
Department	O
of	O
Reproductive	O
Medicine	O
,	O
Omori	O
Hospital	O
.	O

The	O
amoxapine	B:C0002644
-	O
B12	O
group	O
received	O
amoxapine	O
(	O
50	O
mg	O
daily	O
for	O
4	O
weeks	O
,	O
orally	O
)	O
followed	O
(	O
after	O
a	O
1	O
-	O
week	O
washout	O
period	O
)	O
by	O
vitamin	O
B12	I:C0042845
(	O
500	O
μg	O
three	O
-	O
times	O
daily	O
for	O
4	O
weeks	O
)	O
.	O

The	O
amoxapine	O
-	O
B12	B:C0042845
group	O
received	O
amoxapine	O
(	O
50	O
mg	O
daily	O
for	O
4	O
weeks	O
,	O
orally	O
)	O
followed	O
(	O
after	O
a	O
1	O
-	O
week	O
washout	O
period	O
)	O
by	O
vitamin	O
B12	I:C0042845
(	O
500	O
μg	O
three	O
-	O
times	O
daily	O
for	O
4	O
weeks	O
)	O
.	O

The	O
amoxapine	O
-	O
B12	O
group	O
received	O
amoxapine	B:C0002644
(	O
50	O
mg	O
daily	O
for	O
4	O
weeks	O
,	O
orally	O
)	O
followed	O
(	O
after	O
a	O
1	O
-	O
week	O
washout	O
period	O
)	O
by	O
vitamin	O
B12	I:C0042845
(	O
500	O
μg	O
three	O
-	O
times	O
daily	O
for	O
4	O
weeks	O
)	O
.	O

The	O
amoxapine	O
-	O
B12	O
group	O
received	O
amoxapine	O
(	O
50	O
mg	O
daily	O
for	O
4	O
weeks	O
,	O
orally	O
)	O
followed	O
(	O
after	O
a	O
1	O
-	O
week	O
washout	O
period	O
)	O
by	O
vitamin	B:C0042845
B12	I:C0042845
(	O
500	O
μg	O
three	O
-	O
times	O
daily	O
for	O
4	O
weeks	O
)	O
.	O

The	O
B12	B:C0042845
-	O
amoxapine	O
group	O
received	O
the	O
opposite	O
regimen	O
.	O

The	O
B12	O
-	O
amoxapine	B:C0002644
group	O
received	O
the	O
opposite	O
regimen	O
.	O

The	O
B12	O
-	O
amoxapine	O
group	O
received	O
the	O
opposite	O
regimen	B:C0040808
.	O

All	O
pa-tients	O
masturbated	O
to	O
ejaculation	B:C0013746
at	O
least	O
twice	O
during	O
each	O
treatment	O
period	O
.	O

All	O
pa-tients	O
masturbated	O
to	O
ejaculation	O
at	O
least	O
twice	O
during	O
each	O
treatment	B:C0087111
period	O
.	O

The	O
primary	O
outcome	O
was	O
antegrade	B:C0589502
ejaculation	O
of	O
semen	O
,	O
as	O
reported	O
by	O
the	O
patient	O
,	O
on	O
more	O
than	O
one	O
occasion	O
during	O
either	O
treatment	O
period	O
(	O
defined	O
as	O
treatment	O
success	O
)	O
.	O

The	O
primary	O
outcome	O
was	O
antegrade	O
ejaculation	B:C0013746
of	O
semen	O
,	O
as	O
reported	O
by	O
the	O
patient	O
,	O
on	O
more	O
than	O
one	O
occasion	O
during	O
either	O
treatment	O
period	O
(	O
defined	O
as	O
treatment	O
success	O
)	O
.	O

The	O
primary	O
outcome	O
was	O
antegrade	O
ejaculation	O
of	O
semen	B:C2756969
,	O
as	O
reported	O
by	O
the	O
patient	O
,	O
on	O
more	O
than	O
one	O
occasion	O
during	O
either	O
treatment	O
period	O
(	O
defined	O
as	O
treatment	O
success	O
)	O
.	O

The	O
primary	O
outcome	O
was	O
antegrade	O
ejaculation	O
of	O
semen	O
,	O
as	O
reported	O
by	O
the	O
patient	O
,	O
on	O
more	O
than	O
one	O
occasion	O
during	O
either	O
treatment	B:C0087111
period	O
(	O
defined	O
as	O
treatment	O
success	O
)	O
.	O

Any	O
adverse	B:C0877248
events	I:C0877248
were	O
noted	O
.	O

Success	O
rates	O
were	O
compared	O
between	O
treatments	B:C0087111
using	O
Fisher	O
's	I:C1708064
exact	I:C1708064
test	I:C1708064
.	O

Success	O
rates	O
were	O
compared	O
between	O
treatments	O
using	O
Fisher	B:C1708064
's	I:C1708064
exact	I:C1708064
test	I:C1708064
.	O

One	O
patient	O
(	O
B12	B:C0042845
-	O
amoxapine	O
group	O
)	O
withdrew	O
for	O
personal	O
reasons	O
(	O
breakdown	O
of	O
marital	O
relations	O
)	O
;	O
all	O
other	O
patients	O
completed	O
the	O
study	O
.	O

One	O
patient	O
(	O
B12	O
-	O
amoxapine	B:C0002644
group	O
)	O
withdrew	O
for	O
personal	O
reasons	O
(	O
breakdown	O
of	O
marital	O
relations	O
)	O
;	O
all	O
other	O
patients	O
completed	O
the	O
study	O
.	O

Success	O
rate	O
was	O
higher	O
for	O
amoxapine	B:C0002644
than	O
for	O
vitamin	O
B12	I:C0042845
(	O
80	O
%	O
,	O
20/25	O
vs	O
16	O
%	O
,	O
4/25	O
;	O
P<	O
0.0001	O
)	O
.	O

Success	O
rate	O
was	O
higher	O
for	O
amoxapine	O
than	O
for	O
vitamin	B:C0042845
B12	I:C0042845
(	O
80	O
%	O
,	O
20/25	O
vs	O
16	O
%	O
,	O
4/25	O
;	O
P<	O
0.0001	O
)	O
.	O

18	O
patients	O
were	O
responsive	O
to	O
amoxapine	B:C0002644
but	O
not	O
to	O
vitamin	O
B12	I:C0042845
,	O
2	O
patients	O
were	O
responsive	O
to	O
vitamin	O
B12	I:C0042845
but	O
not	O
amoxapine	O
,	O
2	O
patients	O
were	O
responsive	O
to	O
both	O
drugs	O
,	O
and	O
3	O
patients	O
had	O
no	O
response	I:C4282382
to	O
either	O
drug	O
.	O

18	O
patients	O
were	O
responsive	O
to	O
amoxapine	O
but	O
not	O
to	O
vitamin	B:C0042845
B12	I:C0042845
,	O
2	O
patients	O
were	O
responsive	O
to	O
vitamin	O
B12	I:C0042845
but	O
not	O
amoxapine	O
,	O
2	O
patients	O
were	O
responsive	O
to	O
both	O
drugs	O
,	O
and	O
3	O
patients	O
had	O
no	O
response	I:C4282382
to	O
either	O
drug	O
.	O

18	O
patients	O
were	O
responsive	O
to	O
amoxapine	O
but	O
not	O
to	O
vitamin	O
B12	I:C0042845
,	O
2	O
patients	O
were	O
responsive	O
to	O
vitamin	B:C0042845
B12	I:C0042845
but	O
not	O
amoxapine	O
,	O
2	O
patients	O
were	O
responsive	O
to	O
both	O
drugs	O
,	O
and	O
3	O
patients	O
had	O
no	O
response	I:C4282382
to	O
either	O
drug	O
.	O

18	O
patients	O
were	O
responsive	O
to	O
amoxapine	O
but	O
not	O
to	O
vitamin	O
B12	I:C0042845
,	O
2	O
patients	O
were	O
responsive	O
to	O
vitamin	O
B12	I:C0042845
but	O
not	O
amoxapine	B:C0002644
,	O
2	O
patients	O
were	O
responsive	O
to	O
both	O
drugs	O
,	O
and	O
3	O
patients	O
had	O
no	O
response	I:C4282382
to	O
either	O
drug	O
.	O

18	O
patients	O
were	O
responsive	O
to	O
amoxapine	O
but	O
not	O
to	O
vitamin	O
B12	I:C0042845
,	O
2	O
patients	O
were	O
responsive	O
to	O
vitamin	O
B12	I:C0042845
but	O
not	O
amoxapine	O
,	O
2	O
patients	O
were	O
responsive	O
to	O
both	O
drugs	B:C3687832
,	O
and	O
3	O
patients	O
had	O
no	O
response	I:C4282382
to	O
either	O
drug	O
.	O

18	O
patients	O
were	O
responsive	O
to	O
amoxapine	O
but	O
not	O
to	O
vitamin	O
B12	I:C0042845
,	O
2	O
patients	O
were	O
responsive	O
to	O
vitamin	O
B12	I:C0042845
but	O
not	O
amoxapine	O
,	O
2	O
patients	O
were	O
responsive	O
to	O
both	O
drugs	O
,	O
and	O
3	O
patients	O
had	O
no	B:C4282382
response	I:C4282382
to	O
either	O
drug	O
.	O

18	O
patients	O
were	O
responsive	O
to	O
amoxapine	O
but	O
not	O
to	O
vitamin	O
B12	I:C0042845
,	O
2	O
patients	O
were	O
responsive	O
to	O
vitamin	O
B12	I:C0042845
but	O
not	O
amoxapine	O
,	O
2	O
patients	O
were	O
responsive	O
to	O
both	O
drugs	O
,	O
and	O
3	O
patients	O
had	O
no	O
response	I:C4282382
to	O
either	O
drug	B:C3687832
.	O

One	O
patient	O
(	O
4	O
%	O
)	O
reported	O
sleepiness	B:C0013144
and	O
2	O
(	O
8	O
%	O
)	O
reported	O
constipation	O
while	O
receiving	O
amoxapine	O
.	O

One	O
patient	O
(	O
4	O
%	O
)	O
reported	O
sleepiness	O
and	O
2	O
(	O
8	O
%	O
)	O
reported	O
constipation	B:C0009806
while	O
receiving	O
amoxapine	O
.	O

One	O
patient	O
(	O
4	O
%	O
)	O
reported	O
sleepiness	O
and	O
2	O
(	O
8	O
%	O
)	O
reported	O
constipation	O
while	O
receiving	O
amoxapine	B:C0002644
.	O

No	B:C1963761
adverse	I:C1963761
events	I:C1963761
were	O
reported	O
during	O
vitamin	O
B12	I:C0042845
treatment	O
.	O

No	O
adverse	I:C1963761
events	I:C1963761
were	O
reported	O
during	O
vitamin	B:C0042845
B12	I:C0042845
treatment	O
.	O

No	O
adverse	I:C1963761
events	I:C1963761
were	O
reported	O
during	O
vitamin	O
B12	I:C0042845
treatment	B:C0087111
.	O

Amoxapine	B:C0002644
may	O
be	O
an	O
effective	O
,	O
safe	O
and	O
well	O
-	I:C0243095
tolerated	I:C0243095
therapy	O
for	O
retrograde	O
ejaculation	I:C0403673
.	O

Amoxapine	O
may	O
be	O
an	O
effective	O
,	O
safe	O
and	O
well	B:C0243095
-	I:C0243095
tolerated	I:C0243095
therapy	O
for	O
retrograde	O
ejaculation	I:C0403673
.	O

Amoxapine	O
may	O
be	O
an	O
effective	O
,	O
safe	O
and	O
well	O
-	I:C0243095
tolerated	I:C0243095
therapy	B:C0087111
for	O
retrograde	O
ejaculation	I:C0403673
.	O

Amoxapine	O
may	O
be	O
an	O
effective	O
,	O
safe	O
and	O
well	O
-	I:C0243095
tolerated	I:C0243095
therapy	O
for	O
retrograde	B:C0403673
ejaculation	I:C0403673
.	O

